Back to Blog
Clinical Research••9 min read
BPC-157 Human Trial: 87.5% of Knee Pain Patients Report Significant Relief at 6–12 Months
87.5% of patients with chronic knee pain reported significant relief after BPC-157 treatment at the 6–12 month follow-up. Here's a breakdown of the human trial data, the dosing protocol used, and why this peptide is getting serious clinical attention.
PeptIQ Research Team
Editorial
#BPC-157#knee pain#joint health#human-trial#clinical data#peptide therapy#injury recovery#musculoskeletal
Track Your Peptide Protocols
Use PeptIQ to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download PeptIQ
